Synergistic enhancement of anticancer effects on numerous human cancer cell lines treated with the combination of EGCG, other green tea catechins, and anticancer compounds
- 1.4k Downloads
In 2008, we reported that 10 Japanese-size cups of green tea daily, supplemented with tablets of green tea extract (GTE), reduced the recurrence of colorectal adenoma by 51.6 % in patients after polypectomy. Based on these results, we paid special attention to Japanese cancer patients, who consume green tea every day and are administered anticancer drugs. This encouraged us to study whether the combination of green tea catechins and anticancer drugs has the potential to enhance the efficacy of the drugs.
Results and discussion
The combination of GTE and NSAIDs synergistically inhibited tumor development in rodents through the activation of the GADD153–DR5–TRAIL apoptotic pathway. Since then, this study was further extended by various investigators to the combinations of EGCG and other green tea catechins with anticancer compounds, the latter of which include NSAIDs, phytochemicals, and anticancer drugs. In order to demonstrate whether diversity of the combinations would generally induce synergistic anticancer effects on numerous human cancer cell lines, we studied the results of 42 in vitro combination experiments and the synergistic inhibition of tumor volume of 13 combination experiments using xenograft mouse models, which were previously reported by other investigators. The various combinations of EGCG and anticancer compounds induced similar synergistic anticancer effects for both in vitro and in vivo experiments, and showed an average reduction in tumor volume by 70.3 %. Considering the evidence showing that treatment with EGCG inhibited self-renewal of cancer stem cells, the combination shows a great advantage.
Green tea is a cancer preventive for humans, showing a new trend of green tea catechins as synergists with anticancer compounds.
KeywordsApoptosis Cancer stem cells EGCG GADD153 NSAID
Growth arrest and DNA damage-inducible gene 153
Green tea extract
Nonsteroidal anti-inflammatory drugs
TNF-related apoptosis-inducing ligand
We thank Drs. Kei Nakachi and Kazue Imai at Department of Radiobiology/Molecular Epidemiology, Radiation Effects Research Foundation, Hiroshima; Drs. Masahito Shimizu and Hisataka Moriwaki at Department of Medicine, Gifu University; and Mrs. Yoshiaki Kitaoka, Kenta Nakajima, and Dr. Atsushi Takahashi at the Green Tea Laboratory of Saitama Prefectural Agriculture and Forestry Research Center, for their fruitful collaborations and stimulating discussion; and Mrs. Ikuko Shiotani at the Saitama Cancer Center Hospital for her generous collaborations.
Conflict of interest
Here, we declare that we have no conflicts of interest.
- Haque A, Rahman MA, Chen ZG, Shin DM, Amin AR (2014) Combination of erlotinib and epigallocatechin-3-gallate induces apoptosis of squamous cell carcinoma of the head and neck through posttranslational regulation of Bim and Bcl-2. Proc Am Assoc Cancer Res 55:548Google Scholar
- Stearns ME, Amatangelo MD, Varma D, Sell C, Goodyear SM (2010) Combination therapy with epigallocatechin-3-gallate and doxorubicin in human prostate tumor modeling studies: inhibition of metastatic tumor growth in severe combined immunodeficiency mice. Am J Pathol 177:3169–3179PubMedCentralCrossRefPubMedGoogle Scholar
- Tang SN, Singh C, Nall D, Meeker D, Shankar S, Srivastava RK (2010) The dietary bioflavonoid quercetin synergizes with epigallocatechin gallate (EGCG) to inhibit prostate cancer stem cell characteristics, invasion, migration and epithelial-mesenchymal transition. J Mol Signal 5:14PubMedCentralCrossRefPubMedGoogle Scholar
- Yoshida N (1992) Cancer cells talked in this way. Bungeishunju, Ltd, Tokyo, p 267 (Japanese)Google Scholar
- Zhou DH, Wang X, Yang M, Shi X, Huang W, Feng Q (2013) Combination of low concentration of (−)-epigallocatechin gallate (EGCG) and curcumin strongly suppresses the growth of non-small cell lung cancer in vitro and in vivo through causing cell cycle arrest. Int J Mol Sci 14:12023–12036PubMedCentralCrossRefPubMedGoogle Scholar